Webinar Date/Time: Tue, Aug 27, 2024 | 11:00 AM EDT | 4:00 PM BST
This webinar focuses on dose-flexible manufacturing strategies and their role in drug development.
Register Free: https://www.pharmtech.com/pt_w/flexible-dose-development
Event Overview:
This webinar focuses on dose-flexible manufacturing strategies and their role in drug development. Dose flexibility is increasingly important for early clinical studies, particularly in areas such as pediatric medicines and oncology. However, flexible dosing strategies are often neglected or not prioritized early in development. This presentation will focus on technical strategies that can help anticipate appropriate timing for implementation and how to do so cost effectively while adhering to required timelines.
Key Learning Objectives:
Who Should Attend:
Speakers:
Jonathan Cape
Head of Multiparticulate Product Development
Lonza
Jonathan Cape, is Head of Multiparticulate Product Development at Lonza, where he has worked for 13 years in roles ranging from R&D to chemist, to technology manager. Jon earned his PhD in Biochemistry from Washington State University and has held postdoctoral positions at Washington State University and Los Alamos National Laboratory. Jon currently manages Lonza's Multiparticulate Product Development team and is focused on developing impactful patient-centric drug products.
Kaylee Eyerly
Product Development Engineer III
Lonza
Kaylee Eyerly is a Product Development Engineer at Lonza. She has six years of experience in the pharmaceutical industry. She holds a Honors BSc in Chemical Engineering from Oregon State University. She has experience in formulation, process development, and manufacturing in every clinical stage, with specific expertise in late-stage programs, primarily specializing in multiparticulates and spray layered dispersions.
Register Free: https://www.pharmtech.com/pt_w/flexible-dose-development
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.